Wang Yongping, Chen Chen, Hua Qingquan, Wang Lei, Li Fen, Li Man, Mei Zhidan, Zhou Tao, Xiao Bokui, Tao Zezhang
Department of Otolaryngology-Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Research Institute of Otolaryngology‑Head and Neck Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei 430060, P.R. China.
Oncol Rep. 2017 Mar;37(3):1503-1510. doi: 10.3892/or.2017.5377. Epub 2017 Jan 17.
Leucine-rich-α-2-glycoprotein 1 (LRG1) is considered as a potential biomarker as it is aberrantly expressed in various malignancies. However, there is limited information regarding its role in head and neck squamous cell carcinoma (HNSCC). In the present study, we aimed to explore the expression pattern of LRG1 in HNSCC and its clinicopathological significance. We first analyzed LRG1 gene expression in HNSCC by investigating data obtained from the Gene Expression Omnibus (GEO) database. The results showed that LRG1 was downregulated in HNSCC tissues and its expression level was negatively related to tumor T and N stages and degree of malignancy. Then, we further tested a tissue microassay and clinical samples, respectively, by immunohistochemical staining and western blotting. Consistently, the results revealed that LRG1 expression was decreased in tumor tissues regardless of the grade of the tumor. Moreover, the protein level of LRG1 showed slight differences among four T stages or three N stages. In addition, there were no significant associations between LRG1 protein expression and other clinicopathological parameters such as gender, age, tumor location and clinical staging. These findings imply that downregulation of the expression of LRG1 is correlated with tumorigenesis but not with the development of HNSCC, indicating the potential clinical value of LRG1 in the early diagnosis of HNSCC.
富含亮氨酸的α-2-糖蛋白1（LRG1）被认为是一种潜在的生物标志物，因为它在各种恶性肿瘤中异常表达。然而，关于其在头颈部鳞状细胞癌（HNSCC）中的作用的信息有限。在本研究中，我们旨在探讨LRG1在HNSCC中的表达模式及其临床病理意义。我们首先通过研究从基因表达综合数据库（GEO）获得的数据，分析了HNSCC中LRG1基因的表达。结果显示，LRG1在HNSCC组织中表达下调，其表达水平与肿瘤T分期、N分期及恶性程度呈负相关。然后，我们分别通过免疫组织化学染色和蛋白质印迹法对组织芯片和临床样本进行了进一步检测。结果一致显示，无论肿瘤分级如何，肿瘤组织中LRG1的表达均降低。此外，LRG1蛋白水平在四个T分期或三个N分期之间存在细微差异。此外，LRG1蛋白表达与性别、年龄、肿瘤位置和临床分期等其他临床病理参数之间无显著相关性。这些发现表明，LRG1表达下调与肿瘤发生相关，但与HNSCC的发展无关，这表明LRG1在HNSCC早期诊断中具有潜在的临床价值。
